19th Annual International Lung Cancer Congress®
19th Annual International Lung Cancer Congress® July 26 - 28, 2018
Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA
Reservation: (888) 421-1442
The 19th Annual International Lung Cancer Congress®
will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery, and radiation oncology in the clinic. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Bristol-Myers Squibb, Celgene Corporation, Lilly, and Pfizer.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.
Apply testing strategies to identify biomarkers that inform optimized decision-making in the care of patients with lung cancer
Determine emerging evidence concerning the management of patients with non-metastatic lung cancer
Delineate the rationale for optimized and personalized sequencing strategies utilizing clinical trial evidence, performance status, and tumor characteristics
Detail how recent clinical trial results on chemotherapeutic, targeted, and immunotherapeutic strategies can be interpreted in the context of evolving paradigms in the field of lung cancer management
Incorporate recent data sets on single agent and combination immunotherapeutic approaches to care for patients with lung cancer
Report the current status of cooperative group trials that are assessing emerging strategies to treat lung cancer
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT